What you should know:
1. Dexycu is an FDA-approved postoperative steroid designed to simplify the recovery process. Dexycu is single-dose steroid administered at the end of surgery that eliminates the need for a postoperative dosing regimen.
2. Dr. Donnenfeld performed the cataract surgery at Westbury, N.Y.-based Island Eye Surgicenter using Dexycu at its completion.
3. EyePoint is launching Dexycu through a phased rollout, starting with experienced cataract surgeons.
4. EyePoint will make Dexycu available to patients in need of financial assistance through its EyePoint Assist program.
More articles on leadership:
4 ways to reduce SSIs in ASCs
How to proactively tackle physician burnout: Acadia Healthcare CMO Dr. Michael Genovese weighs in
Arizona Medicaid program alerts 3,146 members of privacy breach: 3 details to know
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
